Fibrolamellar hepatocellular carcinoma

This early-stage trial tests a personalized peptide vaccine for people with a rare liver cancer called fibrolamellar hepatocellular carcinoma (FLC) or other tumors that share a specific genetic change (DNAJB1-PRKACA fusion). The vaccine is designed to train the body's immune cell…

This early-phase trial is testing whether combining an immunotherapy drug (nivolumab) with chemotherapy (fluorouracil) and an immune stimulant (interferon alpha 2b) can safely shrink or control fibrolamellar liver cancer that cannot be removed by surgery. The study will enroll 15…

This study is testing a combination of four drugs—atezolizumab, sorafenib, bevacizumab, and cyclophosphamide—in children and young adults with solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the combination can sh…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This phase 2 trial is testing the immunotherapy drug pembrolizumab (Keytruda) in children and young adults up to age 30 with relapsed or hard-to-treat liver cancer. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Researchers will also study how the i…

This study tests whether combining a glutamine-blocking drug (DRP-104) with an immunotherapy (durvalumab) can shrink or control advanced fibrolamellar carcinoma, a rare liver cancer. About 27 people aged 12 and older whose cancer has worsened despite prior treatment will receive …

This early-phase trial tests a peptide vaccine designed to target a specific protein found in fibrolamellar carcinoma (FLC), a rare liver cancer. The vaccine is combined with two immunotherapy drugs (nivolumab and ipilimumab) to boost the immune system's attack on cancer cells. T…